A German firm whose main product is derived from the saliva of the vampire bat is looking to raise more than 70m euros ($91m; Â£49m) on the stock market.Its main drug, desmoteplase, is based on a protein in the bat's saliva.The firm, Paion, said that it hoped to sell 5 million shares - a third of the firm - for 11-14 euros a share.